VIR
Chart
Ratings & dials
1m · 5m · 15m · 1h · 4h · 1DAnalyst & Morningstar ratings
Consensus · Targets · MorningstarThird-party ratings, not SURVYR.'s views.
Health check
See the tests
- ✗Positive net income
- ✗Positive operating cash flow
- ✗Return on assets improved
- ✓Cash flow above net income
- ✓Long-term debt / assets fell
- ✗Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.
Key stats & company
What they do
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Valuation and fundamentals
Valuation & fundamentals
Discounted cash flow
Edit assumptions · recalculates instantly
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.59 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
pricier
cheaper
pricier
Forward EPS $-2.49 vs trailing $-1.76. Forward P/E uses analysts' next-12-month estimate.
Quality & financial health
Piotroski F-score 3/9 · last two fiscal years
Altman Z-score 3.1 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $68.6M | $-438.0M | $-396.6M |
| 2024 | $74.2M | $-522.0M | $-453.7M |
| 2023 | $86.2M | $-615.1M | $-800.4M |
| 2022 | $1.6B | $515.8M | $1.6B |
| 2021 | $1.1B | $528.6M | $-69.4M |
| 2020 | $76.4M | $-298.7M | $-197.5M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR -65.1%.
For information only · Important disclosures
Grades vs sector
Momentum94th percentile in sectorA
Percentile within its GICS sector across the S&P 1500.
Growth100th percentile in sectorA+
Percentile within its GICS sector across the S&P 1500.
ValueNot enough data yet–
Percentile within its GICS sector across the S&P 1500.
Profitability5th percentile in sectorF
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Systematic Models
Not held by any of our 7 live models right now.
Earnings & events
VIR earningsNext report in 7 daysIn line = within 1% of the estimate.
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $238.9M | +23075.1% |
| 2026-03-31 | $-41.0K | – |
| 2025-12-31 | $63.8M | – |
| 2025-09-30 | $-65.0K | – |
| 2025-06-30 | $1.0M | – |
News & catalysts
More newsRating changes
Third-party analyst actions, not SURVYR.'s views. All rating changes
Insider trades
–
Stats refreshed 2026-10-21 18:22:38 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Get the market emails
Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdaysIndexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.
Check your inbox to confirm
We sent a link to . Tap it to start your emails. Nothing is sent until you confirm.
Not there in a minute? Check spam, or .
Dev mode No email provider here, so the confirm link is shown: Open confirm link
Free to use. No card, no ads, no auto-renew.
Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Coteau 0.9 · Oct 21, 2026